The store will not work correctly when cookies are disabled.
8-(4-hydroxybicyclo[2.2.2]octan-1-yl)-1,3-dipropyl-1H-purine-2,6(3H,7H)-dione
ID: ALA218458
PubChem CID: 9950776
Max Phase: Preclinical
Molecular Formula: C19H28N4O3
Molecular Weight: 360.46
Molecule Type: Small molecule
Associated Items:
Names and Identifiers
Canonical SMILES: CCCn1c(=O)c2nc(C34CCC(O)(CC3)CC4)[nH]c2n(CCC)c1=O
Standard InChI: InChI=1S/C19H28N4O3/c1-3-11-22-14-13(15(24)23(12-4-2)17(22)25)20-16(21-14)18-5-8-19(26,9-6-18)10-7-18/h26H,3-12H2,1-2H3,(H,20,21)
Standard InChI Key: JMEHHVKPUQMNOZ-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 29 0 0 0 0 0 0 0 0999 V2000
7.3708 -0.5292 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.0829 -0.9375 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
8.7949 0.2958 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7948 -0.5302 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.5804 -0.7855 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
10.0660 -0.1172 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.5805 0.5510 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.3748 0.2981 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
8.0829 0.7125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.0824 -1.7625 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.3677 -2.1746 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.6535 -1.7617 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.8910 -0.1172 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.3009 -0.8389 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.1223 -0.8409 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.5387 -0.1282 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.1274 0.5881 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.2998 0.5917 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.7375 0.3583 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.7375 -0.4208 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.6560 -0.9410 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
8.0828 1.5375 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.6600 0.7102 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.9458 0.2973 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.2311 0.7093 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.3625 -0.1250 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3 9 1 0
6 13 1 0
13 14 1 0
4 5 1 0
5 6 1 0
6 7 2 0
7 3 1 0
8 9 1 0
13 18 1 0
14 15 1 0
15 16 1 0
16 17 1 0
17 18 1 0
3 4 2 0
13 19 1 0
19 20 1 0
20 16 1 0
8 1 1 0
1 21 2 0
2 10 1 0
9 22 2 0
1 2 1 0
8 23 1 0
10 11 1 0
23 24 1 0
2 4 1 0
24 25 1 0
11 12 1 0
16 26 1 0
M END
Associated Targets(Human)
Associated Targets(non-human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 360.46 | Molecular Weight (Monoisotopic): 360.2161 | AlogP: 2.04 | #Rotatable Bonds: 5 |
Polar Surface Area: 92.91 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 8.42 | CX Basic pKa: 2.47 | CX LogP: 2.25 | CX LogD: 2.22 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.85 | Np Likeness Score: -0.17 |
References
1. Vu CB, Kiesman WF, Conlon PR, Lin KC, Tam M, Petter RC, Smits G, Lutterodt F, Jin X, Chen L, Zhang J.. (2006) Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists., 49 (24): [PMID:17125265] [10.1021/jm060539t] |